Jayaram, H N <br/><br/>
Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells.  [electronic resource] 

 -  Biochemical and biophysical research communications  Aug 1992 
 - 1600-6 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-291X 
<br/><br/><label>Standard No.: </label>10.1016/s0006-291x(05)81591-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Cell Line<br/>Cell Survival--drug effects<br/>Dose-Response Relationship, Drug<br/>Humans<br/>IMP Dehydrogenase--antagonists & inhibitors<br/>Kinetics<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive<br/>Molecular Structure<br/>Nucleosides--pharmacology<br/>Ribavirin--analogs & derivatives<br/>Ribonucleotides--metabolism